Zeitlinger, Markus
Bauer, Martin
Reindl-Schwaighofer, Roman
Stoekenbroek, Robert M.
Lambert, Gilles
Berger-Sieczkowski, Evelyn
Lagler, Heimo
Oesterreicher, Zoe
Wulkersdorfer, Beatrix
Lührs, Petra
Galabova, Gergana
Schwenke, Carsten
Mader, Robert M.
Medori, Rossella
Landlinger, Christine
Kutzelnigg, Alexandra
Staffler, Günther http://orcid.org/0000-0003-0025-5081
Article History
Received: 9 March 2021
Accepted: 20 April 2021
First Online: 10 May 2021
Declarations
:
: The study was conducted at a single centre at the Medical University of Vienna, Austria. The study protocol was approved by the ethics committee of the Medical University of Vienna, Austria (EudraCT: 2015-001719-11; Clinical-Trial-Identifier: NCT02508896) and the Austrian competent authority. The study was performed in accordance with Good Clinical Practice and the Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: All authors have completed and submitted the “ICMJE Form for Disclosure of Potential Conflicts of Interest.” Conflicts of interests have been declared by the following authors: PL, CL, GS AK and GG are or were employees of AFFiRiS AG at the time of the study. RM, CS, and RMM receive honoraria from AFFiRiS AG. RMS is an employee and shareholder of The Medicines Company and Novartis AG, after completion of the study. GL received research funding from AFFiRiS AG. The Medical University of Vienna received financial support for conducting the study. No direct honoraria were obtained by MZ, MB, RRS, EBS, HL, ZO, and BW.